DIPK1B

Across TCGA pan-cancer cohorts, DIPK1B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DIPK1B data layer compared with 28 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher DIPK1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DIPK1B expression acts as an unfavorable survival marker.

PAAD, THYM, and UCEC are the cancer types where DIPK1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.117	0.613	<.001	21	view →
THYM	DFS	Median	All	0.123	0.871	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LIHC	OS	Median	All	0.236	0.707	.013	3	view →
SKCM	OS	Median	All	0.333	0.780	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DIPK1B–PAAD (OS)

Open the PAAD breakdown →